Anika Therapeutics, Inc. (NASDAQ:ANIK) Files An 8-K Financial Statements and Exhibits

Anika Therapeutics, Inc. (NASDAQ:ANIK) Files An 8-K Financial Statements and Exhibits
Item 9.01.Financial Statements and Exhibits.

Story continues below


ExhibitNo. Description
10.1 Negotiated Settlement Agreement and General Release, dated July 13, 2017, by and between Stephen Mascioli, M.D., MPH and Anika Therapeutics, Inc.

[Remainder of page left blank intentionally]

Anika Therapeutics, Inc. Exhibit
EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1     NEGOTIATED SETTLEMENT AGREEMENT AND GENERAL RELEASE   This Negotiated Settlement Agreement (hereinafter the "Agreement") is made by and between Stephen Mascioli,…
To view the full exhibit click here

About Anika Therapeutics, Inc. (NASDAQ:ANIK)

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL.

An ad to help with our costs